文献速递胸部肿瘤

PI3K通路改变驱动MET外显子14跳跃突变NSCLC对MET抑制剂的原发性耐药

Alterations in the PI3K Pathway Drive Resistance to MET Inhibitors in NSCLC Harboring MET Exon 14 Skipping Mutations.
PubMed 文献 · J Thorac Oncol · 2020-03-10

该研究回顾65例METex14跳跃突变NSCLC患者,评估PI3K通路改变与MET TKI原发耐药的关系,并在细胞模型中验证联合PI3K抑制可恢复敏感性。结果显示PI3K通路改变常见,携带改变的患者首次评估即进展,联合PI3K抑制剂可抑制PI3K和MAPK信号并恢复MET TKI疗效。

要点

  • METex14 NSCLC中PI3K通路改变常见,可能与MET TKI原发耐药相关。
  • 携带PI3K通路改变的MET TKI治疗患者首次评估均出现疾病进展。
  • 临床前模型中联合PI3K抑制剂可恢复MET TKI敏感性。

核心结论

  • PI3K通路改变在METex14 NSCLC中常见,可能导致MET TKI原发耐药。
  • 临床前模型中PI3K抑制可恢复MET TKI敏感性。

研究设计与样本

  • 回顾性分析65例METex14跳跃突变NSCLC患者的临床数据。
  • 通过靶向二代测序检测PI3K通路突变,通过免疫组化评估PTEN缺失。
  • 使用原发耐药患者来源细胞系及同时携带METex14突变和PI3K通路改变的细胞系进行体外药物敏感性及信号通路研究。

主要发现

  • 65例样本中2例(3%)检出PIK3CA突变。
  • 26例样本中6例(23%)检出PTEN缺失。
  • 3例携带PI3K通路改变并接受MET TKI治疗的患者首次评估均显示疾病进展。
  • MET TKI对携带PI3K通路改变的METex14突变细胞系(包括PTEN缺失的患者来源细胞系)的增殖无抑制作用。
  • MET TKI联合PI3K抑制剂可同时抑制PI3K和MAPK信号并恢复对MET TKI的敏感性。

临床怎么用

  • 对METex14 NSCLC患者可考虑评估PI3K通路改变以识别MET TKI原发耐药高风险人群。
  • 携带PI3K通路改变的患者可能需要探索MET TKI联合PI3K抑制剂的治疗策略。

局限性

  • PI3K通路改变检测的样本量有限(突变65例、PTEN缺失26例)。
  • 联合PI3K抑制恢复敏感性的证据主要来自临床前细胞模型。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Hepatocyte growth factor receptor (MET) tyrosine kinase inhibitors (MET TKIs) have been found to have efficacy against advanced NSCLC with mutations causing MET exon 14 skipping (METex14 mutations), but primary resistance seems frequent, as response rates are lower than those for targeted TKIs of other oncogene-addicted NSCLCs. Given the known interplay between MET and phosphoinositide 3-kinases (PI3K), we hypothesized that in METex14 NSCLC, PI3K pathway alterations might contribute to primary resistance to MET TKIs. We reviewed clinical data from 65 patients with METex14 NSCLC, assessing PI3K pathway alterations by targeted next-generation sequencing (mutations) and immunohistochemistry (loss of phosphatase and tensin homolog [PTEN]). Using a cell line derived from a patient with primary resistance to a MET TKI and cell lines harboring both a METex14 mutation and a PI3K pathway alteration, we assessed sensitivity to MET TKIs used alone or with a PI3K inhibitor and investigated relevant signaling pathways. We found a phosphatidylinositol 3-kinase catalytic subunit alpha (PIK3CA) mutation in two of 65 samples (3%) and loss of PTEN in six of 26 samples (23%). All three of the MET TKI-treated patients with a PI3K pathway alteration had been found to have progressive disease at first assessment. Likewise, MET TKIs had no effect on the proliferation of METex14-mutated cell lines with a PI3K pathway alteration, including the PTEN-lacking patient-derived cell line. Treatment combining a MET TKI with a PI3K inhibitor caused inhibition of both PI3K and MAPK signaling and restored sensitivity to MET TKIs. PI3K pathway alterations are common in METex14 NSCLC and may confer primary resistance to MET TKIs. In preclinical models, PI3K inhibition restores sensitivity to MET TKIs.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Jamme P, Fernandes M, Copin MC, et al. Alterations in the PI3K Pathway Drive Resistance to MET Inhibitors in NSCLC Harboring MET Exon 14 Skipping Mutations. J Thorac Oncol. 2020. PMID: 32169477. doi:10.1016/j.jtho.2020.01.027

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。